Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Cumulus Neuroscience to Join Bio-Hermes 2 Study with Funding from the Innovate…
Funded by Innovate UK's Small Business Research Initiative (SBRI), this award is focused on enabling organisations with select novel biomarkers to be evaluated as part of the Global Alzheimer's Platform Foundation (GAP) Bio-Hermes 2 Study. Cumulus will deploy AccelADx in the study, a novel, AI-enabled screening test that detects small, subtle changes in brain waves associated with memory recall. Bio-Hermes 2, which aims to generate data to accelerate the adoption and effective use of biomarkers…
PR Newswire
11/07/2024
Oxurion provides clarification on the agenda of the extraordinary general…
Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024Leuven, BELGIUM – July 11, 2024 – 6:00pm CET– Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, announced today it has provided clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 (theEGM ) as set out in the convening notice published on 5 July 2024 in accordance with...
Nasdaq GlobeNewswire
11/07/2024
Groupe Casino - Nombre de droits de vote et d'actions 30-06-2024
CASINO, GUICHARD-PERRACHON Société anonyme au capital de 3 957 404,44 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 30 juin 2024(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers)Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote exerçables en...
Nasdaq GlobeNewswire
11/07/2024
Hormone Replacement Therapy Market Size to be Worth USD 38.8 billion by 2034…
The hormone replacement therapy (HRT) market is experiencing robust growth, driven by increasing awareness of aging-related health issues and the quest for improved quality of life. HRT involves the administration of hormones to alleviate symptoms associated with menopause, andropause, and other hormonal imbalances. The hormone replacement therapy (HRT) market is experiencing robust growth, driven by increasing awareness of aging-related health issues and the quest for improved quality of…
PR Newswire
11/07/2024
Virbac: Termination of the liquidity contract
TERMINATION OF THE LIQUIDITY CONTRACT We inform you of the termination of our liquidity contract since July 1 st, 2024.This contact was in place since February 19, 2019 and suspended since February 3 rd, 2023. A lifelong commitment to animal healthAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat...
Nasdaq GlobeNewswire
11/07/2024
RFID in Pharmaceutical Market to reach USD 7.57 Bn at a CAGR of 7.5 percent by…
The segmentation by type, component, distribution channel, and application aids in understanding the target audience, emerging trends, and market composition. Primary and secondary research techniques are combined in research studies on the RFID in Pharmaceutical market. Both qualitative and quantitative analyses are employed using tools like SWOT, PESTLE, and Porter's Five Forces to guide investment and marketing decisions. The segmentation by type, component, distribution channel, and...
PR Newswire
11/07/2024
GLP-1 Analogues Market Forecast: USD 471.1 Billion by 2032 with a 33.2% CAGR |…
Browse in-depth TOC on "GLP-1 Analogues Market". Browse in-depth TOC on "GLP-1 Analogues Market". 405 - Tables 59 - Figures315 - Pages Ozempic Leads the Charge in the GLP-1 Analogue Market In 2023, Ozempic (semaglutide) dominated the GLP-1 Analogue market, buoyed by its significant revenue contribution and broad global application for diabetes treatment. Its market presence extends to obesity treatment under the brand Wegovy inBrazil, with a notable growth rate of...
PR Newswire
11/07/2024
Vendor Neutral Archive (VNA) Market to be Worth USD 1.3 billion by 2034, Growing…
With VNAs, clinical imaging information can be stored, handled, and archived from diverse sources, eliminating fragmented storage silos. By streamlining data control and making information accessible across healthcare organizations, this consolidation promotes interoperability. Integrated with Electronic Health Records (EHRs), VNAs allow doctors to access clinical photos on a patient's record without delay. By integrating seamlessly, scientists can improve their workflows and create improved…
PR Newswire
11/07/2024
Induced Pluripotent Stem Cells Market Size is Expected to Grow at a CAGR of 9.4%…
The utilization of iPSCs in drug discovery and disease modeling is being accelerated by excessive-throughput screening technologies. Aside from heart disease, liver failure, and diabetes, iPSCs are capable of creating organ replacements. By doing so, the donor organ shortage can be addressed and the impact on affected people can be enhanced. Several wound recuperation treatments are possible with iPSCs, including those that treat excessive burns and chronic ulcers. The utilization of iPSCs in...
PR Newswire
11/07/2024
Injectable Cytotoxic Drug Market to Progress at a CAGR of 6.8%, reaching USD…
The prevalence of cancer has been a key factor that drives the demand for many sectors. Various therapeutics and treatments are required to be given to cancer patients, which drives the demand for such therapies and treatments. The prevalence of cancer has been a key factor that drives the demand for many sectors. Various therapeutics and treatments are required to be given to cancer patients, which drives the demand for such therapies and treatments. The upsurge in rheumatoid arthritis and...
PR Newswire
11/07/2024
Energy Supplement Market Value Set to Total USD 69.4 Billion by 2034, Spurred by…
One of the prominent factors fueling growth of the energy supplement industry is the increasing awareness about health and fitness among consumers. Similarly, growing demand for convenient energy-boosting supplements is set to boost sales growth. One of the prominent factors fueling growth of the energy supplement industry is the increasing awareness about health and fitness among consumers. Similarly, growing demand for convenient energy-boosting supplements is set to boost sales growth...
PR Newswire
11/07/2024
TUMI INTRODUCES LPGA TOUR PRO NELLY KORDA AND PGA TOUR PRO LUDVIG ÅBERG AS THE…
As two of the most committed and celebrated names in golf, Korda and Åberg epitomize a relentless dedication to performance, unwavering drive, and extraordinary results – ideals that TUMI passionately infuses into every collection. The new ambassadors will exclusively carry TUMI luggage and backpacks on tour as the brand supports these players and their ambition to perfect their game. "I'm so excited to partner with TUMI as a global ambassador, representing the brand on tour and...
PR Newswire
11/07/2024
Newest Version of LifeSphere® Regulatory Platform Allows Organizations to…
The new LifeSphere Regulatory Platform ecosystem of products includes: The newLifeSphere Regulatory Platformecosystem of products includes: Industry leaders utilizing LifeSphere Regulatory can further power the platforms' capabilities withLifeSphere NavaX, ArisGlobal's next-generation cognitive computing engine, to leverage the latest GenAI and LLM features. Today, early adopters can leverage GenAI and LLM enhancements that are driving upwards of 50% efficiency gains, including: ...
PR Newswire
11/07/2024
IAS ANNOUNCES 2024 ME AND MY HEALTHCARE PROVIDER CAMPAIGN CHAMPIONS TO HONOR…
Despite a decrease in new acquisition rates, stigma and discrimination remain significant challenges in HIV care. According to the People Living with HIV Stigma Index 2.0 Global Report 2023[1], while 93.5% of respondents were receiving HIV treatment, a majority reported experiencing internalized stigma associated with their HIV status. Additionally, 3% of respondents faced stigma and discrimination from health facility staff and 26.9% admitted to interrupting or stopping their HIV treatment…
PR Newswire
11/07/2024
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major unmet medical needOK-101 demonstrated statistically significant pain relief as measured by visual analogue scale (VAS) from Day 29 through the last study visit at Day 85 in a Phase 2...
Nasdaq GlobeNewswire
11/07/2024
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference…
The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.zymeworks.com/events-and-presentations. About Zymeworks Inc.Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The...
Nasdaq GlobeNewswire
11/07/2024
MGI Tech and Predica Diagnostics Team Up for Precision RNA Sequencing in…
Empowering Precision Medicine Empowering Precision Medicine Predica Diagnostics, renowned for its expertise in cervical cancer screening through its proprietary ciRNAseq-based test, CervicaDx, brings unparalleled precision in identifying high-risk HPV oncogenes and other (pre)malignancy biomarkers. By integrating this advanced diagnostic capability with MGI's robust and affordable DNBSEQ technology, the partnership aims to significantly enhance the accuracy and accessibility of diagnostic...
PR Newswire
11/07/2024
Alvotech Announces Closing of Private Debt Financing
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”). The closing has allowed Alvotech to refinance outstanding debt obligations, reduce the cost of capital and improve its overall debt maturity profile. Following the closing of the Facility, which included the settlement of existing...
Nasdaq GlobeNewswire
11/07/2024
Medit Appoints Han Ryu as CEO, Accelerating Digital Dentistry Innovation
Under Ryu's leadership, Medit aims to strengthen its presence and improve customer service in Europe. This involves establishing a new on-site office and warehouse in Europe to streamline communication and expedite product delivery. Additionally, Medit will introduce a '48-hour product exchange' service aimed at enriching customer experience. Medit is fostering strong partnerships and community initiatives within the dental market. This approach ensures ongoing alignment with market demands and…
PR Newswire
11/07/2024
Implantica announces new health-economics data publication showing RefluxStop™'s…
The study authors represent a partnership between the York Health Economics Consortium, UK and leading reflux centers of excellence in Switzerland, including Dr. med. Yves Borbély, Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, Switzerland, and Prof. Dr. med. Joerg Zehetner, Department of Visceral Surgery, Swiss1Chirurgie, Hirslanden Klinik Beau-Site Switzerland. The study authors represent a partnership between the York Health Economics Consortium, UK and...
PR Newswire
11/07/2024
Official Swiss delegation experiences new frontiers in art tech at HKBU
In his welcoming speech, Dr Clement Chen said the delegation's presence serves as a symbol of the strong ties between Hong Kong and Switzerland, and their shared dedication to excellence and innovation. In his welcoming speech, DrClement Chensaid the delegation's presence serves as a symbol of the strong ties between Hong Kong andSwitzerland, and their shared dedication to excellence and innovation. "HKBU is honoured to be chosen as one of the very few destinations during their tour...
PR Newswire
11/07/2024
NMD Pharma adds new capabilities with several senior recruits to support its…
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipelineAarhus, Denmark, 11 July 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with severe neuromuscular diseases, today announces that it has hired three senior recruits to its management team to support its growing business and pipeline. Peter Kasten will begin as Vice President Finance in August, Cecilia...
Nasdaq GlobeNewswire
11/07/2024
FURNITURE CHINA 2024 Thrives with Enhanced Original Chinese Design and…
Register to get free ticket for Furniture China 2024 and Maison Shanghai 2024 before 1st September. Register to get free ticket forFurnitureChina2024andMaison Shanghai 2024before 1 stSeptember. More Clearer Positioning with Increasing Exhibitor Lineup FurnitureChina2024at SNIEC will exceed past editions, to further promote furniture manufacturing productivity and global trade. Exhibitors from 26 countries will participate, expecting record numbers. Five...
PR Newswire
11/07/2024
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement…
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potentialFS001 targets a novel tumor associated antigen, highly expressed across a range of solid tumors, identified through the application of Foreseen's proprietary proteomic platformsFS001 has demonstrated robust preclinical efficacy in multiple tumor models and exhibits a favorable preclinical safety profile ...
Nasdaq GlobeNewswire
11/07/2024
Altri Comunicati